Paper Details

  1. Home
  2. Paper Details

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.

Author: BarriereSteven L

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Telavancin is a new injectable antibiotic that is effective against many types of bacteria, including MRSA. In clinical trials, it was as effective as vancomycin in treating complicated skin infections, with a cure rate of 87% for telavancin and 86% for vancomycin. The most common side effects were taste disturbance, nausea, vomiting, and foamy urine. Renal problems occurred in 3% of patients taking telavancin and 1% of patients taking vancomycin.
Paper Details　
Original Abstract of the Article :
Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. Telavancin inhibits bacterial cell wall synthesis by interfering with the synthesis of peptidoglycan, and binds to the bacterial membrane and disrupt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fmb.10.138

データ提供：米国国立医学図書館（NLM）

ATLAS Trials: Efficacy and Safety of Telavancin Compared with Vancomycin for the Treatment of Skin Infections

Skin infections, particularly those caused by resistant bacteria, present a significant challenge in infectious disease management. This research evaluates the efficacy and safety of telavancin, a novel lipoglycopeptide antibiotic, in the treatment of complicated skin and skin-structure infections (cSSSI). The study, conducted as part of the Assessment of Telavancin in cSSSI (ATLAS) program, compared telavancin to vancomycin, a standard antibiotic for these infections. The findings demonstrate that telavancin is noninferior to vancomycin in treating cSSSI, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and has a manageable side effect profile.

Telavancin for Complicated Skin Infections

This research highlights the potential of telavancin as an effective and safe treatment option for complicated skin infections, including those caused by MRSA. The study found that telavancin achieved comparable clinical cure rates to vancomycin, demonstrating its effectiveness against these challenging infections. The authors also note that telavancin was well-tolerated, with the most common side effects being taste disturbance, nausea, vomiting, and foamy urine.

Antibiotic Treatment for Skin Infections

This research provides valuable insights for healthcare professionals treating skin infections. The findings support the use of telavancin as a viable alternative to vancomycin for cSSSI, particularly those caused by MRSA. The study emphasizes the importance of careful monitoring for potential side effects, ensuring that patients receive the most effective and safest treatment.

Dr. Camel's Conclusion

Just like a camel adapts to the harsh desert environment, researchers are constantly seeking new and effective ways to combat infections. This research showcases the potential of telavancin as a promising treatment option for complicated skin infections. By understanding the efficacy and safety profile of telavancin, doctors can make informed decisions about antibiotic treatment, ensuring that patients receive the best possible care and achieve a full recovery.

Date :
  1. Date Completed 2011-05-23
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21080861

DOI: Digital Object Identifier

10.2217/fmb.10.138

Related Literature

Article Analysis
・Effects of telavancin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.